Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Genmab A/S (GEN) DKK1

Sell:2,232.00 DKK Buy:2,233.00 DKK Change: 28.00 DKK (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2,232.00 DKK
Buy:2,233.00 DKK
Change: 28.00 DKK (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2,232.00 DKK
Buy:2,233.00 DKK
Change: 28.00 DKK (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact details

Kalvebod Brygge 43
+45 () 70202728

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
148.03 billion DKK
Shares in issue:
65.36 million
Copenhagen Stock Exchange
Danish Krone
OMX Copenhagen 20

Key personnel

  • Deirdre Connelly
    Chairman of the Board
  • Jan van de Winkel
    President and Chief Executive Officer
  • Anthony Pagano
    Chief Financial Officer, Executive Vice President
  • Anthony Mancini
    Chief Operating Officer, Executive Vice President
  • Judith Klimovsky
    Executive Vice President, Chief Development Officer
  • Birgitte Stephensen
    Senior Vice President, IPR & Legal
  • Tahamtan Ahmadi
    Senior Vice President, Oncology
  • Michael Bauer
    Senior Vice President, Head of Operations R&D
  • Marisol Peron
    Corporate Vice President, Communications and Investor Relations
  • Martine van Vugt
    Chief of Staff

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.